美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

藥明生物ADR

8.40

-0.0860-1.01%

盤後：8.400.00000.00%16:00 EST

成交量：1.89萬

成交額：15.96萬

市值：170.96億

市盈率：39.07

高：8.68

開：8.46

低：8.32

收：8.49

52周最高：11.21

52周最低：4.12

股本：20.35億

流通股本：17.74億

量比：0.44

換手率：0.00%

股息：- -

股息率：- -

每股收益(TTM):0.2150

每股收益(LYR):0.2253

淨資產收益率：10.50%

總資產收益率：5.89%

市淨率：2.69

市盈率(LYR):37.29

資料載入中...

總覽公司新聞資訊公告

美國OTC市場藥明生物ADR盤中異動股價大漲5.75%報8.28美元

藥明生物入選恒生可持續發展企業基準指數

藥明生物榮膺弗若斯特沙利文2025年"全球客户價值領導力獎"

美國OTC市場藥明生物ADR盤中異動早盤急速拉昇6.41%報9.63美元

美國OTC市場藥明生物ADR盤中異動早盤大幅下挫5.38%報9.84美元

美國OTC市場藥明生物ADR盤中異動股價大漲5.59%報10.58美元

藥明生物重磅推出WuXia™ 4.0：定點整合細胞株開發平台 TrueSite TI™

藥明生物連續五年入選富時社會責任指數系列

藥明生物榮膺"年度最佳CDMO"等三項IMAPAC獎項

藥明生物近期及淨零排放目標獲科學碳目標倡議（SBTi）認證

藥明生物2025年上半年業績加速增長

藥明生物愛爾蘭工廠通過EMA認證啓動創新生物藥商業化生產

行業領先：藥明生物WuXiUP成功實現中試規模全自動化原液連續生產

藥明生物ADR8月11日成交額為3.98萬美元

藥明生物推出HEK293穩定細胞株構建平台WuXia293 Stable，賦能複雜生物藥分子研發與生產

藥明生物ADR8月8日成交額為27.78萬美元

藥明生物ADR8月7日成交額為45.51萬美元

美國OTC市場藥明生物ADR盤中異動股價大跌5.26%

藥明生物ADR8月6日成交額為21.33萬美元

藥明生物ADR8月5日成交額為11.74萬美元

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/WXXWY/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"WXXWY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"WXXWY\",,,,,undefined,":{"symbol":"WXXWY","market":"US","secType":"STK","nameCN":"藥明生物ADR","latestPrice":8.4,"timestamp":1764968400000,"preClose":8.486,"halted":0,"volume":18929,"hourTrading":{"tag":"盘后","latestPrice":8.4,"preClose":8.4,"latestTime":"16:00 EST","volume":1303,"amount":10945.2,"timestamp":1764968433087},"delay":15,"floatShares":1773747646,"shares":2035256538,"eps":0.214998,"marketStatus":"未開盤","change":-0.086,"latestTime":"12-05 16:00:00 EST 延時","open":8.463,"high":8.68,"low":8.32,"amount":159627.89329999997,"amplitude":0.042423,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":0.214998,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1765184400000},"marketStatusCode":0,"adr":0,"adrRate":2,"exchange":"PINK LIMITED","adjPreClose":8.486,"volumeRatio":0.4440925287797695},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"WXXWY\",,,,,undefined,":{"symbol":"WXXWY","floatShares":1773747646,"roa":"5.89%","roe":"10.50%","lyrEps":0.225273,"volumeRatio":0.4440925287797695,"shares":2035256538,"dividePrice":0,"high":8.68,"amplitude":0.042423,"preClose":8.486,"low":8.32,"week52Low":4.12,"pbRate":"2.69","psRate":"6.02","week52High":11.21,"institutionHeld":0,"latestPrice":8.4,"eps":0.214998,"divideRate":0,"volume":18929,"delay":15,"ttmEps":0.214998,"open":8.463,"prevYearClose":4.4275,"prevWeekClose":8.1,"prevMonthClose":8.1,"prevQuarterClose":10.495,"fiveDayClose":8.1,"twentyDayClose":8.94,"sixtyDayClose":9.3575},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/WXXWY\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-03-26","symbol":"WXXWY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1711425600000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2020-12-10","symbol":"WXXWY","defaultRemindTime":1607610600000,"type":"split","dateTimestamp":1607576400000,"forFactor":1,"toFactor":3,"ratio":0.33}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"WXXWY\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"WXXWY\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2593,"buy":0.5556,"hold":0.1852,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5556,"analysts":27,"updateTime":1756184400000},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"WXXWY\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2586403694","title":"美國OTC市場藥明生物ADR盤中異動 股價大漲5.75%報8.28美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2586403694","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586403694?lang=zh_tw&edition=fundamental","pubTime":"2025-11-24 22:46","pubTimestamp":1763995604,"startTime":"0","endTime":"0","summary":"北京时间2025年11月24日22时46分，美国OTC市场药明生物ADR股票出现异动，股价大幅拉升5.75%。截至发稿，该股报8.28美元/股，成交量1811股，换手率0.00%，振幅0.13%。美国OTC市场药明生物ADR股票所在的生物技术行业中，整体涨幅为0.54%。美国OTC市场药明生物ADR公司简介：无锡药明康德集团是一家生物药物的合同开发和制造组织，简称“CDMO”。无锡药明康德报告称，2020年收入为56亿元人民币，三年复合年增长率为51%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124224644a70e9087&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124224644a70e9087&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["WXXWY","BK4121"],"gpt_icon":0},{"id":"2577388339","title":"藥明生物入選恒生可持續發展企業基準指數","url":"https://stock-news.laohu8.com/highlight/detail?id=2577388339","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577388339?lang=zh_tw&edition=fundamental","pubTime":"2025-10-22 08:30","pubTimestamp":1761093000,"startTime":"0","endTime":"0","summary":"此前，药明生物已入选恒指ESG指数及恒生ESG 50指数。恒生可持续发展企业基准指数旨在评定拥有卓越ESG表现的上市公司，为可持续投资提供基准。药明生物首席执行官、ESG委员会主席陈智胜博士表示：\"入选恒生指数系列，是对我们在可持续发展道路上持续突破的重要认可。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4803088_ZH03088_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU0326950275.SGD","LU1242518857.USD","LU0348735423.USD","LU0140636845.USD","LU0823426308.USD","LU1804176565.USD","LU0511384066.AUD","LU1691799644.USD","LU0417516738.SGD","LU0051755006.USD","LU0181495838.USD","LU0043850808.USD","BK1141","LU2039709279.SGD","BK1576","LU0456827905.SGD","LU0516423091.SGD","LU0516422952.EUR","LU0819121731.USD","LU0289961442.SGD","LU0327786744.USD","LU0359202008.SGD","LU0516423174.USD","LU0672654240.SGD","LU0856984785.SGD","LU2210149790.SGD","02269","LU2095319765.USD","BK1589","LU0307460666.USD","BK4112","BK1610","SG9999002562.SGD","LU0516422440.USD","LU0417516902.SGD","LU3063872942.SGD","LU1242518931.SGD","LU1880383366.USD","LU0109391861.USD","LU2210150020.SGD","LU1720050803.USD","LU0588546209.SGD","LU0320764599.SGD","BK4585","MSCI","PSCI","WXXWY","LU0979878070.USD","IE00B0JY6N72.USD","LU0516422366.SGD"],"gpt_icon":0},{"id":"2577869263","title":"藥明生物榮膺弗若斯特沙利文2025年\"全球客户價值領導力獎\"","url":"https://stock-news.laohu8.com/highlight/detail?id=2577869263","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577869263?lang=zh_tw&edition=fundamental","pubTime":"2025-10-20 17:30","pubTimestamp":1760952600,"startTime":"0","endTime":"0","summary":"上海2025年10月20日 /美通社/ -- 全球领先的合同研究、开发和生产服务公司药明生物宣布，公司荣获弗若斯特沙利文颁发的2025年生物药CRDMO行业 \"全球客户价值领导力奖\"。该奖项表彰了药明生物通过技术创新、卓越运营及对客户需求的前瞻洞察，持续为客户创造卓越价值。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4801893_ZH01893_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["EMA","IE00B0JY6N72.USD","LU0516422440.USD","LU1794554557.SGD","LU0979878070.USD","LU0856984785.SGD","LU0417516738.SGD","WXXWY","LU2039709279.SGD","BK1521","LU0327786744.USD","LU3063872942.SGD","BK4081","LU0326950275.SGD","LU0516423174.USD","LU0516423091.SGD","LU0051755006.USD","LU0181495838.USD","LU0708995583.HKD","LU1720050803.USD","LU0043850808.USD","BK1589","LU0516422366.SGD","BK1610","LU1880383366.USD","LU0819121731.USD","LU0516422952.EUR","BK1576","LU0052750758.USD","LU0307460666.USD","LU0348735423.USD","LU0588546209.SGD","LU1688375341.USD","LU0039217434.USD","BK1141","LU0359202008.SGD","LU0417516902.SGD","LU0823426308.USD","LU0823426480.USD","LU0359201612.USD","LU1242518857.USD","LU0140636845.USD","BK4121","LU1242518931.SGD","SG9999002463.SGD","LU0456846285.SGD","LU0456827905.SGD","LU0320764599.SGD","02269","LU0348825331.USD"],"gpt_icon":0},{"id":"2575695253","title":"美國OTC市場藥明生物ADR盤中異動 早盤急速拉昇6.41%報9.63美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2575695253","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575695253?lang=zh_tw&edition=fundamental","pubTime":"2025-10-13 22:36","pubTimestamp":1760366180,"startTime":"0","endTime":"0","summary":"北京时间2025年10月13日22时36分，美国OTC市场药明生物ADR股票出现波动，股价快速拉升6.41%。截至发稿，该股报9.63美元/股，成交量416股，换手率0.00%，振幅1.77%。美国OTC市场药明生物ADR股票所在的生物技术行业中，整体涨幅为0.31%。美国OTC市场药明生物ADR公司简介：无锡药明康德集团是一家生物药物的合同开发和制造组织，简称“CDMO”。无锡药明康德报告称，2020年收入为56亿元人民币，三年复合年增长率为51%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101322362094c6b615&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101322362094c6b615&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4121","WXXWY"],"gpt_icon":0},{"id":"2574690437","title":"美國OTC市場藥明生物ADR盤中異動 早盤大幅下挫5.38%報9.84美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2574690437","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574690437?lang=zh_tw&edition=fundamental","pubTime":"2025-10-10 21:46","pubTimestamp":1760103988,"startTime":"0","endTime":"0","summary":"北京时间2025年10月10日21时46分，美国OTC市场药明生物ADR股票出现异动，股价急速下跌5.38%。截至发稿，该股报9.84美元/股，成交量4812股，换手率0.00%，振幅0.48%。美国OTC市场药明生物ADR股票所在的生物技术行业中，整体跌幅为0.28%。美国OTC市场药明生物ADR公司简介：无锡药明康德集团是一家生物药物的合同开发和制造组织，简称“CDMO”。无锡药明康德报告称，2020年收入为56亿元人民币，三年复合年增长率为51%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251010214628a6b319bc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251010214628a6b319bc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4121","WXXWY"],"gpt_icon":0},{"id":"2571655463","title":"美國OTC市場藥明生物ADR盤中異動 股價大漲5.59%報10.58美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2571655463","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571655463?lang=zh_tw&edition=fundamental","pubTime":"2025-09-29 22:42","pubTimestamp":1759156922,"startTime":"0","endTime":"0","summary":"北京时间2025年09月29日22时42分，美国OTC市场药明生物ADR股票出现波动，股价大幅上涨5.59%。截至发稿，该股报10.58美元/股，成交量251股，换手率0.00%，振幅0.00%。美国OTC市场药明生物ADR股票所在的生物技术行业中，整体涨幅为1.81%。美国OTC市场药明生物ADR公司简介：无锡药明康德集团是一家生物药物的合同开发和制造组织，简称“CDMO”。无锡药明康德报告称，2020年收入为56亿元人民币，三年复合年增长率为51%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250929224202a6a68537&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250929224202a6a68537&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4121","WXXWY"],"gpt_icon":0},{"id":"2570483004","title":"藥明生物重磅推出WuXia™ 4.0：定點整合細胞株開發平台 TrueSite TI™","url":"https://stock-news.laohu8.com/highlight/detail?id=2570483004","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570483004?lang=zh_tw&edition=fundamental","pubTime":"2025-09-25 19:43","pubTimestamp":1758800580,"startTime":"0","endTime":"0","summary":"上海2025年9月25日 /美通社/ -- 全球领先的合同研究、开发和生产服务公司药明生物今日宣布推出行业领先的定点整合CHO细胞株开发平台TrueSite TI。关于WuXia细胞株构建系列平台 WuXia是药明生物开发的高产哺乳动物细胞株构建系列平台，产量最高可达11克/升。WuXia平台历经技术迭代，TrueSite TI是最新推出的WuXia4.0平台，通过行业领先的定点整合技术，显著增强细胞株表达量和稳定性，大幅提升细胞株开发效率。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4783196_ZH83196_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU1720050803.USD","LU0516423091.SGD","LU0516422952.EUR","LU0039217434.USD","LU0417516738.SGD","BK1576","LU0051755006.USD","LU0856984785.SGD","SG9999002562.SGD","LU0327786744.USD","LU0588546209.SGD","LU0823426308.USD","LU0320764599.SGD","LU0516423174.USD","LU0456846285.SGD","IE00B0JY6N72.USD","LU0456827905.SGD","LU0307460666.USD","LU0819121731.USD","LU1880383366.USD","LU2039709279.SGD","LU0417516902.SGD","LU0359202008.SGD","BK1141","LU0572944931.SGD","LU0181495838.USD","LU1242518857.USD","LU1242518931.SGD","LU0348825331.USD","LU0348735423.USD","LU0516422440.USD","BK1610","02269","LU0043850808.USD","LU0979878070.USD","LU1794554557.SGD","LU0052750758.USD","BK1589","BK4121","LU0359201612.USD","LU0823426480.USD","SG9999002463.SGD","LU0708995583.HKD","LU0516422366.SGD","LU0140636845.USD","BK1521","LU0326950275.SGD","WXXWY","LU1688375341.USD"],"gpt_icon":0},{"id":"2569761760","title":"藥明生物連續五年入選富時社會責任指數系列","url":"https://stock-news.laohu8.com/highlight/detail?id=2569761760","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569761760?lang=zh_tw&edition=fundamental","pubTime":"2025-09-23 12:00","pubTimestamp":1758600000,"startTime":"0","endTime":"0","summary":"上海2025年9月23日 /美通社/ --全球领先的合同研究、开发和生产服务公司药明生物宣布，公司凭借在可持续发展领域的卓越表现入选\"富时社会责任指数系列\"，公司已连续五年获得此项认可。药明生物首席执行官、ESG委员会主席陈智胜博士表示：\"我们十分荣幸再次入选富时社会责任指数系列，这项认可将激励我们坚定推进可持续发展战略。被纳入富时社会责任指数系列的企业均需满足一系列ESG相关标准。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4780904_ZH80904_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU0516422952.EUR","LU0109391861.USD","LU0456827905.SGD","LU0979878070.USD","LU1720050803.USD","LU0516422440.USD","LU1688375341.USD","02269","LU1242518857.USD","SG9999002562.SGD","LU0181495838.USD","LU0320764599.SGD","LU0043850808.USD","IE00BKPKM429.USD","LU2095319765.USD","LU0289960550.SGD","LU0175139822.USD","SG9999002463.SGD","LU1880383366.USD","BK1141","MSCI","LU0708995583.HKD","BK1610","WXXWY","LU0051755006.USD","PSCI","LU0348735423.USD","LU0359201612.USD","LU0456846285.SGD","BK1576","LU0039217434.USD","LU0289961442.SGD","LU0516422366.SGD","LU1267930730.SGD","BK4585","LU2039709279.SGD","LU2210149790.SGD","LU0823426308.USD","LU0417516902.SGD","BK4588","LU2265009873.SGD","IE00B0JY6N72.USD","LU0140636845.USD","LU0348825331.USD","LU0327786744.USD","BK4121","LU1794554557.SGD","LU0819121731.USD","LU0672654240.SGD","LU0708995401.HKD"],"gpt_icon":0},{"id":"2566714978","title":"藥明生物榮膺\"年度最佳CDMO\"等三項IMAPAC獎項","url":"https://stock-news.laohu8.com/highlight/detail?id=2566714978","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566714978?lang=zh_tw&edition=fundamental","pubTime":"2025-09-12 09:30","pubTimestamp":1757640600,"startTime":"0","endTime":"0","summary":"自2017年以来，药明生物已多次在IMAPAC举办的各类奖项评选中获奖。药明生物首席执行官陈智胜博士表示：\"我们非常高兴药明生物再次获得IMAPAC颁发的多项大奖，充分体现了客户以及行业对我们所创造价值的认可。截至2025年6月底，药明生物帮助客户研发和生产的综合项目高达864个，其中包括24个商业化生产项目。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4771384_ZH71384_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU0979878070.USD","LU0417516738.SGD","LU0819121731.USD","LU0456846285.SGD","LU0052750758.USD","BK1576","LU0823426480.USD","BK1141","LU0140636845.USD","SG9999002463.SGD","WXXWY","LU0051755006.USD","LU1242518857.USD","LU1688375341.USD","BK4121","LU1880383366.USD","BK4139","LU0572944931.SGD","BK1521","LU0359202008.SGD","LU1242518931.SGD","LU0307460666.USD","BK1610","LU0327786744.USD","LU0320764599.SGD","LU0516423174.USD","LU0326950275.SGD","LU2039709279.SGD","LU0181495838.USD","LU0456827905.SGD","LU0348825331.USD","02269","LU0516422440.USD","LU0348735423.USD","LU0516423091.SGD","LU0516422952.EUR","LU0043850808.USD","LU0039217434.USD","LU0359201612.USD","BK1589","LU0856984785.SGD","SG9999002562.SGD","LU0823426308.USD","LU1720050803.USD","LU0516422366.SGD","LU0708995583.HKD","LU1794554557.SGD","CDMO","LU0588546209.SGD","LU0417516902.SGD"],"gpt_icon":1},{"id":"2563052696","title":"藥明生物近期及淨零排放目標獲科學碳目標倡議（SBTi）認證","url":"https://stock-news.laohu8.com/highlight/detail?id=2563052696","media":"美通社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563052696?lang=zh_tw&edition=fundamental","pubTime":"2025-08-28 17:00","pubTimestamp":1756371600,"startTime":"0","endTime":"0","summary":"药明生物是行业内首批获SBTi近期及净零减排目标认证的企业之一。药明生物首席执行官、ESG委员会主席陈智胜博士表示：\"我们很开心公司的近期及净零温室气体目标已经顺利获得SBTi认证。药明生物SBTi目标矩阵 净零目标到2050年实现全价值链温室气体净零排放。关于SBTi 科学碳目标倡议 是一家企业气候行动组织，旨在帮助全球企业和金融机构在应对气候变化方面发挥应有作用。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4761029_ZH61029_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU0109391861.USD","WRI","LU0823426480.USD","BK1141","LU0175139822.USD","BK1610","LU0588546209.SGD","LU0819121731.USD","MSCI","LU0327786744.USD","BK4121","LU0320764599.SGD","PSCI","LU0051755006.USD","LU0052750758.USD","LU0672654240.SGD","LU0516423174.USD","BK4585","IE00B0JY6N72.USD","LU0708995583.HKD","LU0511384066.AUD","LU1267930730.SGD","LU2039709279.SGD","SG9999002463.SGD","02269","LU0326950275.SGD","LU0516422952.EUR","LU2095319765.USD","BK1589","BK1576","LU0289739343.SGD","LU0359202008.SGD","LU1794554557.SGD","LU0516422366.SGD","WXXWY","LU0516423091.SGD","BK1521","LU0359201612.USD","LU0572944931.SGD","LU0823426308.USD","LU2265009873.SGD","LU2210150020.SGD","LU0039217434.USD","LU0516422440.USD","LU0708995401.HKD","LU0856984785.SGD","LU1688375341.USD","LU1242518931.SGD","LU1242518857.USD","LU0043850808.USD"],"gpt_icon":1},{"id":"2560319995","title":"藥明生物2025年上半年業績加速增長","url":"https://stock-news.laohu8.com/highlight/detail?id=2560319995","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560319995?lang=zh_tw&edition=fundamental","pubTime":"2025-08-19 20:01","pubTimestamp":1755604860,"startTime":"0","endTime":"0","summary":"研究业务  集团打造了多个业界领先的生物药发现技术平台，在2025年保持强劲增长。开发业务  2025年上半年，集团新增了86个综合开发项目，进一步巩固了其拥有业界最大复杂生物药产品线之一的领先地位。生产业务  截至2025年6月30日，集团支持了67个临床III期项目和24个商业化生产项目，并计划在2025年完成25个PPQ。此外，药明合联生产基地已实现机械完工，并预计在2025年底正式投入运营，在2026年初开始GMP生产。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4754491_ZH54491_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU0359201612.USD","LU2039709279.SGD","LU0823426480.USD","LU0516422440.USD","BK1610","LU0417516902.SGD","LU0588546209.SGD","BK4081","BK1589","LU0823426308.USD","BK1576","LU1242518857.USD","LU0320764599.SGD","LU0327786744.USD","LU0456827905.SGD","LU0307460666.USD","LU0516423091.SGD","LU1242518931.SGD","LU0819121731.USD","LU0516423174.USD","LU0456846285.SGD","IE00B0JY6N72.USD","LU0052750758.USD","LU0039217434.USD","LU0181495838.USD","BK4121","ADC","BK1141","LU0140636845.USD","LU1794554557.SGD","WBS","BK1521","BK4211","LU0348735423.USD","LU0326950275.SGD","LU0979878070.USD","LU0708995583.HKD","LU0516422366.SGD","LU1880383366.USD","WXXWY","BK4231","LU0516422952.EUR","SG9999002562.SGD","SG9999002463.SGD","EMA","LU0417516738.SGD","LU0043850808.USD","LU0348825331.USD","02269"],"gpt_icon":1},{"id":"2560133188","title":"藥明生物愛爾蘭工廠通過EMA認證 啓動創新生物藥商業化生產","url":"https://stock-news.laohu8.com/highlight/detail?id=2560133188","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560133188?lang=zh_tw&edition=fundamental","pubTime":"2025-08-18 12:00","pubTimestamp":1755489600,"startTime":"0","endTime":"0","summary":"自2023年以来，药明生物多个生产基地已相继获得EMA和美国FDA批准，为该款产品提供商业化生产服务。爱尔兰基地实现商业化生产突破 此次获批也标志着药明生物爱尔兰基地商业化生产服务正式扬帆起航。出色质量体系屡获全球认可 截至2024年底，药明生物始终以100%的成功率顺利通过42次国际药品监管机构检查，累计获得97项生产许可证。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4753183_ZH53183_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU2039709279.SGD","BK1141","LU1242518857.USD","EMA","LU0051755006.USD","LU0516423091.SGD","LU1720050803.USD","BK1589","LU0140636845.USD","LU0456827905.SGD","LU0516422366.SGD","WXXWY","BK1576","LU0181495838.USD","LU0823426480.USD","LU0348735423.USD","LU0819121731.USD","SG9999002463.SGD","LU0326950275.SGD","LU0856984785.SGD","LU0588546209.SGD","IE00B0JY6N72.USD","LU0823426308.USD","LU0979878070.USD","LU0043850808.USD","LU0516422440.USD","BK4081","LU0456846285.SGD","LU0307460666.USD","LU0516423174.USD","LU1688375341.USD","02269","LU0572944931.SGD","LU0417516738.SGD","BK1521","LU0320764599.SGD","LU0359201612.USD","LU0417516902.SGD","LU0039217434.USD","LU0348825331.USD","BK4121","LU1880383366.USD","LU0359202008.SGD","LU0516422952.EUR","LU1242518931.SGD","LU1794554557.SGD","SG9999002562.SGD","LU0327786744.USD","BK1610","LU0708995583.HKD"],"gpt_icon":0},{"id":"2558442640","title":"行業領先：藥明生物WuXiUP成功實現中試規模全自動化原液連續生產","url":"https://stock-news.laohu8.com/highlight/detail?id=2558442640","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558442640?lang=zh_tw&edition=fundamental","pubTime":"2025-08-12 17:00","pubTimestamp":1754989200,"startTime":"0","endTime":"0","summary":"药明生物在成功实现WuXiUP中试规模全连续生产的基础上，通过引入膜层析、自动化控制等前沿技术，并对PAT技术进行迭代优化，进一步实现中试规模的全自动化原液连续生产。经升级的WuXiUP全自动化连续生产平台将在提升生产效率和产品质量方面发挥更大作用，赋能客户加速生物药从研发到商业化的全流程。WuXiUP全自动连续生产线通过全线集成自动化系统，可实现24/7小时不间断高效运转，大幅减少人工操作环节，降低产品质量风险，提升生产效率。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4749500_ZH49500_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU0588546209.SGD","LU0516422440.USD","LU0516422952.EUR","LU0140636845.USD","LU0327786744.USD","LU0572944931.SGD","LU0819121731.USD","SG9999002463.SGD","BK1610","LU1720050803.USD","LU0456827905.SGD","LU1794554557.SGD","LU0051755006.USD","LU0359201612.USD","LU0456846285.SGD","LU0516423091.SGD","LU0181495838.USD","WXXWY","LU0039217434.USD","LU0823426308.USD","LU1688375341.USD","LU0856984785.SGD","LU2039709279.SGD","LU0348825331.USD","LU0348735423.USD","LU0417516738.SGD","BK1589","02269","BK4121","LU0043850808.USD","LU0052750758.USD","LU0516422366.SGD","BK1141","LU0516423174.USD","LU0359202008.SGD","LU0979878070.USD","LU0708995583.HKD","LU1242518857.USD","LU1242518931.SGD","LU1880383366.USD","SG9999002562.SGD","BK1521","LU0326950275.SGD","LU0417516902.SGD","LU0823426480.USD","BK1576","LU0307460666.USD","LU0320764599.SGD","IE00B0JY6N72.USD"],"gpt_icon":0},{"id":"2558643957","title":"藥明生物ADR8月11日成交額為3.98萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2558643957","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558643957?lang=zh_tw&edition=fundamental","pubTime":"2025-08-12 16:37","pubTimestamp":1754987871,"startTime":"0","endTime":"0","summary":"美东时间2025年8月11日，药明生物ADR成交额为3.98万美元，成交额较昨日减少85.67%，当日成交量为5280.00股。药明生物ADR于2025年8月11日涨0.8%，报7.56美元，该股过去5个交易日跌4.3%，年初至今涨70.65%，过去60日涨25.79%。它成立于 2010 年，隶属于药明康德，并于 2017 年在香港联交所上市。无锡药明康德报告称，2020年收入为56亿元人民币，三年复合年增长率为51%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250812172909a483cece&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250812172909a483cece&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4121","WXXWY"],"gpt_icon":0},{"id":"2558695940","title":"藥明生物推出HEK293穩定細胞株構建平台WuXia293 Stable，賦能複雜生物藥分子研發與生產","url":"https://stock-news.laohu8.com/highlight/detail?id=2558695940","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558695940?lang=zh_tw&edition=fundamental","pubTime":"2025-08-11 16:30","pubTimestamp":1754901000,"startTime":"0","endTime":"0","summary":"WuXia293Stable平台具备显著优势，可大幅提升蛋白表达量，实现人源糖基化，还能最大化地降低或避免复杂难表达分子中常见的蛋白质截短或断裂问题，从而显著提升产品质量。WuXia293Stable细胞株在长期传代培养期间，始终保持稳定的表达水平与产品质量，助力实现不同规模的临床和商业化生产。药明生物依托其专有的HEK 293 宿主细胞株成功开发了WuXia293Stable平台。WuXia293Stable的单克隆抗体分批补料表达量高达5.0克 / 升，同时产物纯度得到显著提升。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4748257_ZH48257_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1589","LU0043850808.USD","LU1794554557.SGD","LU0588546209.SGD","LU0516422952.EUR","LU1880383366.USD","BK1576","LU0417516902.SGD","LU0516422366.SGD","LU2039709279.SGD","LU0417516738.SGD","LU0823426480.USD","BK1521","LU0320764599.SGD","LU0856984785.SGD","LU0456827905.SGD","SG9999002562.SGD","LU0348825331.USD","LU0326950275.SGD","LU1242518857.USD","LU0051755006.USD","LU1242518931.SGD","LU0819121731.USD","LU0572944931.SGD","LU0307460666.USD","LU0516423091.SGD","BK1610","LU0516423174.USD","02269","LU0456846285.SGD","LU0039217434.USD","WXXWY","LU0052750758.USD","SG9999002463.SGD","BK1141","BK4121","LU0140636845.USD","LU0348735423.USD","LU0516422440.USD","LU0708995583.HKD","LU0359201612.USD","LU0327786744.USD","LU0823426308.USD","LU1688375341.USD","LU1720050803.USD","IE00B0JY6N72.USD","LU0979878070.USD","LU0181495838.USD","LU0359202008.SGD"],"gpt_icon":0},{"id":"2558219509","title":"藥明生物ADR8月8日成交額為27.78萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2558219509","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558219509?lang=zh_tw&edition=fundamental","pubTime":"2025-08-09 16:36","pubTimestamp":1754728576,"startTime":"0","endTime":"0","summary":"美东时间2025年8月8日，药明生物ADR成交额为27.78万美元，成交额较昨日减少38.96%，当日成交量为3.71万股。药明生物ADR于2025年8月8日跌2.22%，报7.5美元，该股过去5个交易日跌4.21%，年初至今涨69.3%，过去60日涨27.12%。它成立于 2010 年，隶属于药明康德，并于 2017 年在香港联交所上市。无锡药明康德报告称，2020年收入为56亿元人民币，三年复合年增长率为51%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250809163621a6dc4f9b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250809163621a6dc4f9b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4121","WXXWY"],"gpt_icon":0},{"id":"2557523564","title":"藥明生物ADR8月7日成交額為45.51萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557523564","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557523564?lang=zh_tw&edition=fundamental","pubTime":"2025-08-08 16:31","pubTimestamp":1754641891,"startTime":"0","endTime":"0","summary":"美东时间2025年8月7日，药明生物ADR成交额为45.51万美元，成交额较昨日增加113.37%，当日成交量为5.91万股。药明生物ADR于2025年8月7日跌4.01%，报7.67美元，该股过去5个交易日跌6.12%，年初至今涨73.14%，过去60日涨28.05%。它成立于 2010 年，隶属于药明康德，并于 2017 年在香港联交所上市。无锡药明康德报告称，2020年收入为56亿元人民币，三年复合年增长率为51%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808180511a47d074e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808180511a47d074e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4121","WXXWY"],"gpt_icon":0},{"id":"2557313562","title":"美國OTC市場藥明生物ADR盤中異動 股價大跌5.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2557313562","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557313562?lang=zh_tw&edition=fundamental","pubTime":"2025-08-07 22:39","pubTimestamp":1754577581,"startTime":"0","endTime":"0","summary":"北京时间2025年08月07日22时39分，美国OTC市场药明生物ADR股票出现波动，股价急速下挫5.26%。美国OTC市场药明生物ADR股票所在的生物技术行业中，整体跌幅为0.17%。美国OTC市场药明生物ADR公司简介：无锡药明康德集团是一家生物药物的合同开发和制造组织，简称“CDMO”。它成立于 2010 年，隶属于药明康德，并于 2017 年在香港联交所上市。无锡药明康德报告称，2020年收入为56亿元人民币，三年复合年增长率为51%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080722394194d5bb0b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080722394194d5bb0b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4121","WXXWY"],"gpt_icon":0},{"id":"2557563915","title":"藥明生物ADR8月6日成交額為21.33萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557563915","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557563915?lang=zh_tw&edition=fundamental","pubTime":"2025-08-07 16:23","pubTimestamp":1754555032,"startTime":"0","endTime":"0","summary":"美东时间2025年8月6日，药明生物ADR成交额为21.33万美元，成交额较昨日增加81.62%，当日成交量为2.67万股。药明生物ADR于2025年8月6日跌0.5%，报7.99美元，该股过去5个交易日跌2.92%，年初至今涨80.36%，过去60日涨36.58%。它成立于 2010 年，隶属于药明康德，并于 2017 年在香港联交所上市。无锡药明康德报告称，2020年收入为56亿元人民币，三年复合年增长率为51%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807173053a47aa04b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807173053a47aa04b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4121","WXXWY"],"gpt_icon":0},{"id":"2557324838","title":"藥明生物ADR8月5日成交額為11.74萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557324838","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557324838?lang=zh_tw&edition=fundamental","pubTime":"2025-08-06 16:14","pubTimestamp":1754468064,"startTime":"0","endTime":"0","summary":"美东时间2025年8月5日，药明生物ADR成交额为11.74万美元，成交额较昨日增加12.57%，当日成交量为1.45万股。药明生物ADR于2025年8月5日涨1.65%，报8.03美元，该股过去5个交易日跌4.63%，年初至今涨81.26%，过去60日涨39.65%。它成立于 2010 年，隶属于药明康德，并于 2017 年在香港联交所上市。无锡药明康德报告称，2020年收入为56亿元人民币，三年复合年增长率为51%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806165519a6d63313&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806165519a6d63313&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["WXXWY","BK4121"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":49,"code":"91000000","status":"200"}]}}